## Breadcrumb

- [Home](/)
- [About Us](/about-us)
- [Press Room](/about-us/press-room)
- [Press Releases](/about-us/press-room/press-releases)
 
  ## Breadcrumb

- [Home](/)
- [About Us](/about-us)
- [Press Room](/about-us/press-room)
- [Press Releases](/about-us/press-room/press-releases)
 
 #  Breaking News: FDA Approves Treatment for “Off” Periods in Parkinson’s 

 

   

 **ARDSLEY, NY (December 27, 2018)** — The U.S. Food and Drug Administration (FDA) has approved INBRIJA™, a levodopa inhalation powder developed by Acorda Therapeutics, as a treatment for “off” periods in people with Parkinson’s disease (PD) who are treated with [carbidopa/levodopa](https://www.parkinson.org/living-with-parkinsons/treatment/prescription-medications/levodopa).

**Quick Facts about INBRIJA™:**

- INBRIJA™ is the first and only FDA-approved inhaled levodopa for intermittent treatment of “off” periods in people with PD taking carbidopa/levodopa.
- This new treatment is expected to be available in the first quarter of 2019.

For more information about INBRIJA™ and other PD treatments, contact the [Parkinson’s Foundation](https://www.parkinson.org/) Helpline at 1-800-4PD-INFO (473-4636) or [Helpline@Parkinson.org](mailto:helpline@parkinson.org). You can also read more about INBRIJA™ [in this press release](https://www.businesswire.com/news/home/20181221005620/en/Acorda-Therapeutics-Announces-FDA-Approval-INBRIJA%E2%84%A2-levodopa) from Acorda Therapeutics.

More information about ways to manage “off” time can be found in our podcast episode [*How to Manage Parkinson’s “Off” Time*](https://www.parkinson.org/library/podcast/5).

 \###

**About the Parkinson’s Foundation**  
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $400 million in Parkinson’s research and clinical care. Connect with us on [Parkinson.org](http://www.parkinson.org/), [Facebook](http://www.facebook.com/ParkinsonDotOrg), [Twitter](http://www.twitter.com/ParkinsonDotOrg), [Instagram](http://www.instagram.com/ParkinsonDotOrg/) or call (800) 4PD-INFO (473-4636).

**About Parkinson’s Disease**  
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the U.S. alone.

 

 

 ###  Monthly Gifts 

 Your ongoing support provides steady funding that we can count on to remain innovative in our work to make life better for people with Parkinson’s.

 [GIVE MONTHLY](?form=FUNMJGMXKTW%3FappealCode%3DGeneral&recurring=monthly) 

 

 

 

  - Share on Facebook
- Share on X
- Share on LinkedIn